Navigation Links
Research discovery may lead to advances in heart disease and cancer treatment

New Orleans, LA Research led by T. Cooper Woods, PhD, Assistant Professor of Pharmacology and Experimental Therapeutics at LSU Health Sciences Center New Orleans, and Director of the Molecular Cardiology Research Laboratory at Ochsner Clinic Foundation, has identified the mechanism of how a drug commonly used on stents to prevent reclosure of coronary arteries, regulates cell movement which is critical to wound healing and the progression of diseases like cancer. The study is published in the April 16th issue of the Journal of Biological Chemistry.

The antibiotic, rapamycin, is used on drug-eluting stents implanted during angioplasty because it is effective in preventing restenosis (re-narrowing or reclosure) of arteries. However, rapamycin can also prevent tissue from growing over and covering the metal stents, a critical part of the artery's healing after angioplasty. Without this protective covering, blood clots can develop many months later, called late stent thrombosis. These clots can lead to a heart attack.

"Late stent thrombosis has emerged as a major factor diminishing the benefits of drug-eluting stents, highlighting the need for a better understanding of the antimigratory mechanism of rapamycin and its analogs," notes Dr. Woods.

Through a series of experiments, the researchers found that by silencing a protein made by cells exposed to mTOR inhibitors, a class of drugs including rapamycin, they could block rapamycin's inhibitory effect on cell migration.

"We identified specific changes in proteins that a class of drugs, called mTOR inhibitors, uses to block cell movement," said Dr. Woods. "This knowledge will help us to better design strategies to help arteries heal following angioplasty or to prevent tumor growth."

Studies like this one often have application beyond the original research question because they identify basic mechanisms involved in many biologic processes. Cell migration in cancer is not only important in tumor growth, but also in the spread of cancer to other sites in the body.

Heart disease is the leading cause of death in the United States. Coronary heart disease is the most common type of heart disease. According to the American Heart Association, in 2006, an estimated 1.3 million angioplasty procedures were performed. It has been estimated that about 60% of angioplasty procedures performed now are performed with drug-eluting stents.

Cancer is the second most common cause of death in the US, accounting for nearly 1 of every 4 deaths.


Contact: Leslie Capo
Louisiana State University Health Sciences Center

Related biology news :

1. UI researchers analyze implications of intelligent design for human behavior
2. New nano-tool synthesized at Scripps Research Institute
3. Stanford researchers find electrical current stemming from plants
4. Selected highlights of the research being presented at the Experimental Biology 2010 meeting
5. EPA hosts decontamination research and development conference
6. American Association for Cancer Research hosts 101st Annual Meeting 2010 in Washington, D.C.
7. UCLA researchers make first direct recording of mirror neurons in human brain
8. Scripps Research scientists solve mystery of fragile stem cells
9. International research team discovers novel genes influencing kidney disease risk
10. MIT researchers harness viruses to split water
11. Autism Speaks awards 16 new research grants funding more than $5 million over next 3 years
Post Your Comments:
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
(Date:5/24/2016)... -- Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the ... latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology: